Page 30 - Heca News Today

State legislatures are wrestling with how much to restrict or expand abortion access after the U.S. Supreme Court overturned Roe v. Wade last year.

Swedish medical equipment maker Getinge reported on Wednesday an unexpected rise in first-quarter operating profit as demand for some equipment picked up from the pandemic and component shortages eased.

GSK began 2023 with a quarterly performance that beat analyst expectations and extended a series of positive results following strong sales of its roster of vaccines as well as HIV and respiratory medicines.

Novartis on Tuesday raised its full-year earnings outlook after cutting costs, a breast cancer drug trial success and progress in boosting output of a radiotherapy drug against prostate cancer.

General Electric Co on Tuesday raised the low end of its full-year profit forecast after quarterly profit topped Wall Street estimates as strong air travel demand drove up sales of jet engine spare parts and services.

Contaminated cough syrup made by an Indian company has been found in the Marshall Islands and Micronesia, the World Health Organization (WHO) said on Tuesday, after a spate of child deaths linked to other syrups in some countries last year.

China's foreign ministry said on Tuesday that all inbound travellers will only need to show COVID-19 antigen tests result taken within 48 hours before boarding flights starting April 29, dropping the PCR test requirement.

Spain is bracing for a week of temperatures as high as 40C that are forecast to shatter records for April, as officials weighed opening public swimming pools early and adapting school schedules and meteorologists warned of the risk of wildfires.

Novartis said no signs of liver damage had been seen in trials testing its anti-inflammatory drug candidate remibrutinib so far, voicing cautious optimism that it could elude the side effects that have beset rival products in the same drug class.

Dutch health technology company Philips on Monday said it had set aside 575 million euros ($631 million) for possible litigation costs related to its global recall of respiratory machines.